Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase Inhibitors

Design, Synthesis and Structure-activity Studies of Rhodanine Derivatives as HIV-1 Integrase Inhibitors

Raltegravir was the first HIV-1 integrase inhibitor that gained FDA approval for use in the treatment of HIV-1 infection. Because of the emergence of IN inhibitor-resistant viral strains, there is a need to identify innovative second-generation IN inhibitors. Previously, we identified 2-thioxo-4-thi...

Full description

Bibliographic Details
Main Authors: Kavya Ramkumar, Vladimir N. Yarovenko, Alexandra S. Nikitina, Igor V. Zavarzin, Mikhail M. Krayushkin, Leonid V. Kovalenko, Adrian Esqueda, Srinivas Odde, Nouri Neamati
Format: Article
Language:English
Published: MDPI AG 2010-06-01
Series:Molecules
Subjects:
rhodanine
HIV-1
integrase
APE1
2-thioxo-4-thiazolidinone
docking
Online Access:http://www.mdpi.com/1420-3049/15/6/3958/

Internet

http://www.mdpi.com/1420-3049/15/6/3958/

Similar Items